TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31923017

Group type: EXPERIMENTAL
Intervention: 5 mL of 2% lidocaine with 1:100,000 adrenaline
Number of subjects: 40

Group type: COMPARATOR
Intervention: 5 mL of saline solution (control group)
Number of subjects: 40
Study: 31437010

Group type: EXPERIMENTAL
Intervention: High-dose D. farinae Drops
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Medium-dose D. farinae Drops
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study: 28891253

Group type: EXPERIMENTAL
Intervention: Desmopressin plus Suoquan
Number of subjects: 369

Group type: COMPARATOR
Intervention: Behavioral intervention
Number of subjects: 369

Group type: COMPARATOR
Intervention: Desmopressin
Number of subjects: 369
Study: 25482023

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) at doses of 30 Gy/15 or 25 Gy/10
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Not receiving PCI (Control)
Number of subjects: 155
Study: 23649684

Group type: EXPERIMENTAL
Intervention: UPPP
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: UPPP with RTBR
Number of subjects: 47
Study: 21851594

Group type: EXPERIMENTAL
Intervention: Trial and error technique
Number of subjects: 175

Group type: COMPARATOR
Intervention: Errorless learning method
Number of subjects: 175
Study: 19197266

Group type: EXPERIMENTAL
Intervention: sibutramine plus lifestyle modification (combined therapy)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: sibutramine alone
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 194

Group type: COMPARATOR
Intervention: lifestyle modification alone
Number of subjects: 194
Study: 16889120

Group type: EXPERIMENTAL
Intervention: Apple pectin-chamomile extract (Diarrhoesan)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 15599313

Group type: EXPERIMENTAL
Intervention: basiliximab + steroids
Number of subjects: 140

Group type: COMPARATOR
Intervention: basiliximab + placebo
Number of subjects: 140
Study: 11412828

Group type: EXPERIMENTAL
Intervention: APSGN children
Number of subjects: 0
Study: 9154284

Group type: EXPERIMENTAL
Intervention: 0.12% isopropyl unoprostone
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5% timolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: isopropyl unoprostone
Number of subjects: 0
Study: 9115686

Group type: EXPERIMENTAL
Intervention: Potassium chloride dentifrice (KCl)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Potassium chloride and sodium monofluorphosphate dentifrice (KCl + MFP)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 62
Study: 2954458

Group type: EXPERIMENTAL
Intervention: Two-needle vaccination
Number of subjects: 423

Group type: COMPARATOR
Intervention: One-needle vaccination
Number of subjects: 423
Study: 31659214

Group type: EXPERIMENTAL
Intervention: Blurred vision under no-pressure condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blurred vision under tonal-pressure condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blurred vision under tonal + time pressure condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal vision under no-pressure condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal vision under tonal-pressure condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal vision under tonal + time pressure condition
Number of subjects: 0
Study: 29609899

Group type: EXPERIMENTAL
Intervention: Tailored Multimedia Intervention (technology + tailored counseling)
Number of subjects: 160
Study: 27842543

Group type: EXPERIMENTAL
Intervention: Integrated care centers providing core HIV services (HIV counseling and testing, education, condom distribution, needle exchange, opioid therapy, STI management, TB screening, ART)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (no integrated care centers)
Number of subjects: 0
Study: 24114397

Group type: EXPERIMENTAL
Intervention: Genistein 54 mg daily
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study: 22905105

Group type: EXPERIMENTAL
Intervention: BCG treatment
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: EBV infection
Number of subjects: 6
Study: 20618313

Group type: EXPERIMENTAL
Intervention: Magnesium Administration Rank (MAR)
Number of subjects: 114
Study: 18999169

Group type: EXPERIMENTAL
Intervention: Automated, unsupervised, iterative pattern learning approach for constructing a medical dictionary of disease terms.
Number of subjects: 100
Study: 14977310

Group type: EXPERIMENTAL
Intervention: 5% sodium hypochloride (NaOCI)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 3% hydrogen peroxide (H2O2)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combination of H2O2 and NaOCl
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gluconate
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Formocresol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (irrigated with water)
Number of subjects: 14
Study: 11697572

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 9250111

Group type: EXPERIMENTAL
Intervention: Calcium intake of 1200 mg Ca/d
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Calcium intake of 1300 mg Ca/d
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Calcium intake > 2 g/d
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Calcium intake (general)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Calcium retention modeling
Number of subjects: 35
Study: 8176052

Group type: EXPERIMENTAL
Intervention: Equal-variance condition
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cross-channel covariance condition
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cross-parameter covariance condition
Number of subjects: 6
Study: 3234410

Group type: EXPERIMENTAL
Intervention: Lidocaine (100 mg bolus followed by 2 mg min‐1 infusion)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Propafenone (105 mg bolus followed by 300 mg orally every 8 h)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 29947648

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 17
Study: 27026482

Group type: EXPERIMENTAL
Intervention: Oral azithromycin (one dose)
Number of subjects: 829
Study: 25171035

Group type: EXPERIMENTAL
Intervention: Subepithelial connective tissue graft (CTG)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Class V composite resin restoration (CRR)
Number of subjects: 26
Study: 23160309

Group type: EXPERIMENTAL
Intervention: Single-step test (SST)
Number of subjects: 0
Study: 20064881

Group type: EXPERIMENTAL
Intervention: GTH treatment effects
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Self‐regulation
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Social‐cognitive variables
Number of subjects: 661
Study: 18534485

Group type: EXPERIMENTAL
Intervention: Metal-on-metal hip resurfacing devices
Number of subjects: 337
Study: 17038453

Group type: COMPARATOR
Intervention: Doxycycline 100 mg twice daily for 10 days followed by placebo (placebo group)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice daily for 10 days followed by continued doxycycline 100 mg twice daily over 4 months (doxycycline group)
Number of subjects: 37
Study: 12529867

Group type: EXPERIMENTAL
Intervention: Parametric gamma frailty model applied to long-term follow-up survival data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parametric test statistic for testing proportional odds assumption
Number of subjects: 0
Study: 11071595

Group type: EXPERIMENTAL
Intervention: Energy-enriched formula (1.5 kcal/mL)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard formula (1 kcal/mL)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both formulas
Number of subjects: 27
Study: 8923869

Group type: EXPERIMENTAL
Intervention: Two 200‐mg testosterone pellets (400 mg, 3 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Four 200‐mg testosterone pellets (800 mg, 6 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Four 200‐mg testosterone pellets (800 mg, 6 mg/day) plus a single im injection of 300 mg depot medroxyprogesterone acetate (DMPA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All three regimens (two T pellets, four T pellets, and four T pellets plus DMPA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: DMPA
Number of subjects: 30
Study: 1526045

Group type: EXPERIMENTAL
Intervention: Laser cautery
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sub-mucosal diathermy (SMD)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study: 4018502

Group type: EXPERIMENTAL
Intervention: Morphine (100 micrograms/kg body wt as a bolus intravenously)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Atropine (7 micrograms/kg body wt as a bolus)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Naloxone (40 micrograms/kg body wt as a bolus, followed by 10 micrograms/kg body wt X h)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 16
Study: 31477047

Group type: EXPERIMENTAL
Intervention: Continuous oxytocin infusion
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Placebo infusion (discontinued oxytocin)
Number of subjects: 1200
Study: 29590534

Group type: EXPERIMENTAL
Intervention: High-intensity exercise (HIEX)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Ibuprofen (IBU) 300 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Water and HIEX
Number of subjects: 15

Group type: COMPARATOR
Intervention: Water and rest
Number of subjects: 15

Group type: COMPARATOR
Intervention: IBU and rest
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: IBU and HIEX
Number of subjects: 15
Study: 27237200

Group type: COMPARATOR
Intervention: SRP only
Number of subjects: 24

Group type: COMPARATOR
Intervention: SRP and PDT (1% methylene blue solution)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SRP, PDT, and LLLT
Number of subjects: 24
Study: 25121804

Group type: EXPERIMENTAL
Intervention: Acetaminophen ER 1300 mg three times daily
Number of subjects: 542

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 542
Study: 22382344

Group type: EXPERIMENTAL
Intervention: Certolizumab and golimumab (anti-TNF treatment)
Number of subjects: 2710

Group type: COMPARATOR
Intervention: DMARD (nonbiological disease-modifying antirheumatic drug)
Number of subjects: 2710
Study: 20137821

Group type: EXPERIMENTAL
Intervention: Dopamine (4 microg/kg/min)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dobutamine (4 microg/kg/min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (Control Group)
Number of subjects: 30
Study: 17698968

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pentobarbital/midazolam/fentanyl regimen
Number of subjects: 60
Study: 12890127

Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg plus metoclopramide 10 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sumatriptan 50 mg plus placebo
Number of subjects: 16
Study: 10716471

Group type: EXPERIMENTAL
Intervention: Moderate renal insufficiency in the SOLVD Prevention Trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate renal insufficiency in the SOLVD Treatment Trial
Number of subjects: 0
Study: 9013267

Group type: EXPERIMENTAL
Intervention: Electrocardiogram (ECG) abnormalities in patients with systemic sclerosis
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Conduction disturbances
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Infarction pattern
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Non-specific ST-T wave changes
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Right ventricular hypertrophy
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: QTc interval
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Long QTc interval
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Non-specific ST-T wave abnormalities
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Electrocardiographic signs of right ventricular hypertrophy
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combination of right ventricular hypertrophy, right atrial enlargement and right bundle branch block
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Standard ECG
Number of subjects: 72
Study: 1546723

Group type: EXPERIMENTAL
Intervention: 60-minute infusion/glycopyrrolate pretreatment
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 30-minute infusion/glycopyrrolate pretreatment
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 60-minute infusion/placebo pretreatment
Number of subjects: 51

Group type: COMPARATOR
Intervention: 30-minute infusion/placebo pretreatment
Number of subjects: 51
Study: 4048086

Group type: EXPERIMENTAL
Intervention: Great Sensations Program (nutrition-education project)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 0
Study: 31577765

Group type: EXPERIMENTAL
Intervention: Electronic Foot and Ankle Outcome Score (EFAOS)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Paper Foot and Ankle Outcome Score (PFAOS)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Preference for methodology
Number of subjects: 227
Study: 28288496

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 92
Study: 25953357

Group type: EXPERIMENTAL
Intervention: Active IOM (3.7 μg/kg) + Active AMPH (0.1 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo IOM + Active AMPH (0.1 mg/kg)
Number of subjects: 12
Study: 23333104

Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study: 21457864

Group type: EXPERIMENTAL
Intervention: Miniscrews
Number of subjects: 24

Group type: COMPARATOR
Intervention: Utility arches
Number of subjects: 24
Study: 19646081

Group type: EXPERIMENTAL
Intervention: Talipexole hydrochloride tablets alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Talipexole hydrochloride tablets with Madopar (co-beneldopa)
Number of subjects: 0
Study: 17462549

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (100 mg intramuscularly for 3 months)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (optimally conventional treatment of CKD)
Number of subjects: 29
Study: 14718433

Group type: EXPERIMENTAL
Intervention: Intranasal Moli1901 (10 micro mol/L)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intranasal Moli1901
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 12563960

Group type: EXPERIMENTAL
Intervention: Levofloxacin (200 mg orally once daily, 200/100 mg twice daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Cefuroxime (250 mg orally twice daily)
Number of subjects: 90
Study: 8810062

Group type: EXPERIMENTAL
Intervention: Accelerated intake (same-day appointment)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard intake (1- to 7-day delay)
Number of subjects: 78
Study: 1433666

Group type: EXPERIMENTAL
Intervention: Collagen-impregnated prosthesis
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nonimpregnated prosthesis
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Vascular group (patients with vascular disease)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cholecystectomy (control group)
Number of subjects: 41
Study: 6376951

Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed protein‐glucose (PHP‐G) diet
Number of subjects: 16

Group type: COMPARATOR
Intervention: Crystalline amino acid‐glucose (CAA‐G) diet
Number of subjects: 16
Study: 31251694

Group type: EXPERIMENTAL
Intervention: Interval cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interval cytoreductive surgery (CRS)
Number of subjects: 0
Study: 29439612

Group type: EXPERIMENTAL
Intervention: Nomogram based on risk factors (largest LN metastasis diameter, number of metastatic LNs, extent of extranodal invasion)
Number of subjects: 1788

Group type: EXPERIMENTAL
Intervention: Training set for nomogram development
Number of subjects: 1788

Group type: EXPERIMENTAL
Intervention: Testing and validation sets for nomogram validation
Number of subjects: 1788
Study: 27553435

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (TC)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Paclitaxel plus cisplatin (TP)
Number of subjects: 244
Study: 25048075

Group type: EXPERIMENTAL
Intervention: Small-sided games (SSG)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Cycling (CYC)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sedentary control (CON)
Number of subjects: 33
Study: 22964355

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 152

Group type: COMPARATOR
Intervention: Rest time
Number of subjects: 152
Study: 20858539

Group type: EXPERIMENTAL
Intervention: Acitretin loaded Nanostructured Lipid Carriers (ActNLCs) gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Act plain gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ActNLCs loaded gel
Number of subjects: 0
Study: 18797859

Group type: COMPARATOR
Intervention: Stented group (n = 58)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Nonstented group (n = 57)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 115
Study: 15860245

Group type: EXPERIMENTAL
Intervention: Pulse-wave velocity (PWV)
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Brachial-ankle PWV
Number of subjects: 1004
Study: 12640369

Group type: EXPERIMENTAL
Intervention: 100% oxygen (OxR)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Room air (RAR)
Number of subjects: 106
Study: 10657332

Group type: EXPERIMENTAL
Intervention: Amoxicillin 40 mg/kg/day in three doses
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 8676539

Group type: EXPERIMENTAL
Intervention: High-energy food (HE, 2520 kcal/d, 10.5 MJ)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Regular hospital food (RHF, 1670 kcal/d, 7.0 MJ)
Number of subjects: 36
Study: 1501354

Group type: EXPERIMENTAL
Intervention: PAR3 group (3 mL of MVI‐Pediatric supplement, parenterally fed)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PAR2 group (2 mL, parenterally fed)
Number of subjects: 30

Group type: COMPARATOR
Intervention: ENT group (enterally fed)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PAR3 group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PAR2 group
Number of subjects: 30

Group type: COMPARATOR
Intervention: ENT group
Number of subjects: 30
Study: 31561325

Group type: EXPERIMENTAL
Intervention: Combined exercises (aerobic + resistance exercises)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aerobic exercises
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cardio tennis exercises
Number of subjects: 30
Study: 30573707

Group type: EXPERIMENTAL
Intervention: Autologous dental material (ADM)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (no filling of post-extraction socket)
Number of subjects: 9
Study: 29111980

Group type: EXPERIMENTAL
Intervention: Metformin continued group
Number of subjects: 268

Group type: COMPARATOR
Intervention: Metformin discontinued group
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 268
Study: 25877422

Group type: EXPERIMENTAL
Intervention: Auto-crosslinked hyaluronic acid gel (3 ml)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (Foley balloon catheter only)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Auto-crosslinked hyaluronic acid gel
Number of subjects: 120
Study: 24037003

Group type: EXPERIMENTAL
Intervention: Radial shockwave treatment (three applications, once a week)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional physiotherapy (ten sessions comprising ultrasound, kinesiotherapy, and guidance for home-based stretching)
Number of subjects: 40
Study: 21273897

Group type: EXPERIMENTAL
Intervention: Vibration treatment (30-min duration at 30 mins after and 1, 2, 3, and 4 days after exercise)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Vibration treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 15
Study: 20635451

Group type: EXPERIMENTAL
Intervention: Hinged ankle-foot orthoses (AFOs)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Typically developing (TD) children
Number of subjects: 21
Study: 17961721

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tandem transplants and post-transplant maintenance treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Graft purging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel drugs (bortezomib, thalidomide, lenalidomide)
Number of subjects: 0
Study: 15781177

Group type: EXPERIMENTAL
Intervention: Partner-guided pain management training intervention
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual care control condition
Number of subjects: 78
Study: 11925463

Group type: EXPERIMENTAL
Intervention: Daily supplementation with 80 mg of zinc as zinc oxide plus 2 mg of copper as cupric oxide
Number of subjects: 3640

Group type: COMPARATOR
Intervention: No zinc and copper supplementation (control group)
Number of subjects: 3640
Study: 9620100

Group type: EXPERIMENTAL
Intervention: bromfenac 25 mg
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: naproxen sodium 550 mg
Number of subjects: 310

Group type: COMPARATOR
Intervention: acetaminophen 325 mg
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: bromfenac 25 mg (fed)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: bromfenac 25 mg (fasted)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: naproxen sodium 550 mg (fed)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: naproxen sodium 550 mg (fasted)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: adverse effects
Number of subjects: 310
Study: 8904472

Group type: EXPERIMENTAL
Intervention: New catheter (Hewlett Packard HP 13975 A)
Number of subjects: 8